RxDoctor Payments Data

Joseph Spinale, DO

Cardiovascular Disease · Oneida, NYNPI 1215931035

Payments from drug & device makers

$597in general payments, 2019–2025

Across 28 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$186
  • Novartis$112
  • Baxter Healthcare$72
  • Cvrx, Inc.$66
  • Biotronik Inc.$36
  • Merck$34
  • plus $90 from 3 others

What the payments were for

  • Consulting fees$193%
  • Food & beverage$54691%
  • Education$336%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$597 in reported general payments places this provider in the 30th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$67,107
Medicare patients
1,287
Services billed
3,026

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$258,257
EntrestoSacubitril/Valsartan178$246,952
XareltoRivaroxaban113$149,210
FarxigaDapagliflozin Propanediol19$18,752
Ambrisentan12$14,925
JardianceEmpagliflozin19$11,693
Metoprolol Succinate586$7,966
Amiodarone Hcl73$2,222
PaceroneAmiodarone Hcl11$1,514
Torsemide71$1,377
Atorvastatin Calcium111$1,070
Losartan Potassium147$993
Flecainide Acetate36$949
Dilt-XrDiltiazem Hcl36$923
Rosuvastatin Calcium31$786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$112$246,952178 claims
AstraZenecaFarxiga$186$18,75219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Oneida

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →